Compare Bank of Nova Scotia (BNS) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Cytokinetics Inc — how do they compare? Bank of Nova Scotia trades at $90.22 (market cap $108.17B), while Cytokinetics Inc trades at $82.64 (market cap $11.12B). The key difference: Bank of Nova Scotia is far larger — about 9.7× Cytokinetics Inc's market cap, and Bank of Nova Scotia pays a 3.61% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BNS | CYTK | |
|---|---|---|
Market Cap | $108.17B | $11.12B |
Sector | Financials | Technology |
52-Week High | $88.99 | $87.26 |
52-Week Low | $54.50 | $33.23 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $11.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.00, up 0.47% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 earnings beating expectations, revenue growth to $37.1B, and a healthy 24.86% net income margin. Recent acquisition of MapleMark Bank supports strategic growth initiatives while the dividend increase to $1.14 signals management confidence.
BNS presents a compelling investment case with consistent earnings beats, attractive dividend yield, and strategic expansion. However, elevated valuation multiples and macroeconomic sensitivity in the banking sector warrant caution. Analyst consensus remains positive with 53% buy ratings, though the stock trades near resistance levels requiring careful entry timing.
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
